X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LOA2 met its primary endpoint of non-inferiority vs. comparator at the 3-month time point in corneal staining with a p value of 0.001. LO2A continued, as in prior trials, to demonstrate a good safety profile with no major adverse events or side effects reported.
Lead Product(s): Sodium Hyaluronate
Therapeutic Area: Ophthalmology Product Name: LO2A
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
The clinical trial is designed to demonstrate the clinical efficacy and safety of LO2A in DES patients with Sjögren's syndrome. Phase IV study aims at expanding LO2A's current approved status.
Lead Product(s): Sodium Hyaluronate
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
Details:
This agreement will advance Wize Pharma's ongoing clinical program for LO2A, currently in a Phase IV study for the treatment of dry eye syndrome in patients with Sjogren's.
Lead Product(s): Sodium Hyaluronate
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bonus BioGroup
Deal Size: $7.4 million Upfront Cash: Undisclosed
Deal Type: Agreement January 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
